Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics

ObjectivesPosterior reversible encephalopathy syndrome (PRES) is a rare but potentially severe complication of VEGF-pathway inhibition. A recent FAERS analysis supported PRES as a probable class effect of angiogenesis inhibitors but found no association with continuous VEGFR affinity, did not formal...

Полное описание

Библиографические подробности

Главные авторы:	Ji Li, Yan Cheng, Yunzhou Yang
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2026-07-01
Серии:	Frontiers in Pharmacology
Предметы:	disproportionality analysis FAERS fruquintinib pharmacovigilance posterior reversible encephalopathy syndrome ramucirumab
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1887454/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!